XTX Topco Ltd Reduces Stake in Trevi Therapeutics, Inc. $TRVI

Key Points

• XTX Topco Ltd significantly reduced its stake in Trevi Therapeutics, decreasing its holdings by 84.6% during the first quarter, now owning 10,380 shares valued at $65,000.
• Several analysts have set varied ratings and price targets for Trevi Therapeutics, with an average price target of $20.38 and a general sentiment of "Buy" among analysts.
• Trevi Therapeutics recently reported earnings of ($0.09) per share for the last quarter, which exceeded analyst expectations of ($0.10).

XTX Topco Ltd reduced its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 84.6% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,380 shares of the company's stock after selling 56,821 shares during the quarter. XTX Topco Ltd's holdings in Trevi Therapeutics were worth $65,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Two Sigma Investments LP bought a new position in Trevi Therapeutics in the 4th quarter worth about $560,000. Ameriprise Financial Inc. increased its position in shares of Trevi Therapeutics by 187.0% during the 4th quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock valued at $399,000 after purchasing an additional 63,067 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Trevi Therapeutics during the 1st quarter valued at about $197,000. Renaissance Technologies LLC increased its position in shares of Trevi Therapeutics by 42.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock valued at $414,000 after purchasing an additional 29,700 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Trevi Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 482,815 shares of the company's stock valued at $1,989,000 after purchasing an additional 49,173 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Stock Performance

TRVI traded up $0.10 on Wednesday, hitting $7.42. 1,010,461 shares of the company were exchanged, compared to its average volume of 1,632,637. The firm has a fifty day simple moving average of $6.73 and a two-hundred day simple moving average of $6.11. Trevi Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $8.11. The stock has a market capitalization of $903.61 million, a PE ratio of -17.67 and a beta of 0.58.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, equities analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TRVI. Wall Street Zen lowered Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Cantor Fitzgerald began coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price objective on the stock. Needham & Company LLC reduced their price objective on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Raymond James Financial reduced their price objective on Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $20.38.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.